Skip to content
Home/Companies/Biotech/Vaximm

Vaximm

Biotech·Germany·Exited 2022·Held 11yr
Entry
2011
Hold
11yr
Exit
2022

Who owns Vaximm?

Vaximm is a German Biotech company, now owned by NEC OncoImmunity, which acquired it in 2022 from Sunstone Life Science Ventures.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures III · 2007 · VC

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
NEC OncoImmunity
Exit Year
2022

More from Sunstone Life Science Ventures III

Other portfolio companies in the same fund.

MinervaX
MinervaX
Active
BiotechDenmark· 2014
Cantargia
Exited 2015
BiotechSweden· 2013
Opsona Therapeutics
Exited 2019
BiotechIreland· 2013
Follicum
Exited 2014
BiotechSweden· 2012
to Swedish Growth Fund
Galecto
Exited 2020
BiotechDenmark· 2012
Orphazyme
Orphazyme
Exited 2017
BiotechDenmark· 2011
to Eurazeo

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Vaximm?

Vaximm is now owned by NEC OncoImmunity, which acquired it in 2022 from Sunstone Life Science Ventures.

When did NEC OncoImmunity acquire Vaximm?

NEC OncoImmunity acquired Vaximm in 2022, buying from Sunstone Life Science Ventures.

Who did Vaximm sell to?

Sunstone Life Science Ventures sold Vaximm to NEC OncoImmunity in 2022 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue